Results indicate that anti-TIGIT treatment mitigated lymphocyte depletion and sepsis mortality in cancer (CA) septic mice but not in previously healthy (PH) mice, illuminating a potential therapeutic target for septic patients with preexisting malignancy. This evidence concerns the gene TIGIT and Sepsis.